Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment
Control of <i>Mycobacterium tuberculosis</i> infection continues to be an issue, particularly in countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The effort to reduce the catastrophic cost of TB with the WHO's End TB Strategy in 2035 is still...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_7bb350a2c56640cd92cf47bca8fe5f3d | ||
042 | |a dc | ||
100 | 1 | 0 | |a Filia Stephanie |e author |
700 | 1 | 0 | |a Mutiara Saragih |e author |
700 | 1 | 0 | |a Usman Sumo Friend Tambunan |e author |
245 | 0 | 0 | |a Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment |
260 | |b MDPI AG, |c 2021-04-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics13050592 | ||
500 | |a 1999-4923 | ||
520 | |a Control of <i>Mycobacterium tuberculosis</i> infection continues to be an issue, particularly in countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The effort to reduce the catastrophic cost of TB with the WHO's End TB Strategy in 2035 is still obstructed by the emergence of drug-resistant TB (DR-TB) cases as result of various mutations of the MTB strain. In the approach to combat DR-TB, several potential antitubercular agents were discovered as inhibitors for various existing and novel targets. Host-directed therapy and immunotherapy also gained attention as the drug-susceptibility level of the pathogen can be reduced due to the pathogen's evolutionary dynamics. This review is focused on the current progress and challenges in DR-TB treatment. We briefly summarized antitubercular compounds that are under development and trials for both DR-TB drug candidates and host-directed therapy. We also highlighted several problems in DR-TB diagnosis, the treatment regimen, and drug discovery that have an impact on treatment adherence and treatment failure. | ||
546 | |a EN | ||
690 | |a tuberculosis | ||
690 | |a drug-resistance | ||
690 | |a drug discovery and development | ||
690 | |a host-directed therapy | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 13, Iss 5, p 592 (2021) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/13/5/592 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/7bb350a2c56640cd92cf47bca8fe5f3d |z Connect to this object online. |